BIS.US ProShares UltraShort Nasdaq Biotechnology
- Total assets
- 1.67M
- Expense ratio
- 0.96%
- Dividend yield
- 5.95%
- 1-year return
- -46.77%
- Holdings
- 104
- Since
- 2010
Fund data as reported by the issuer, updated Nov 14, 2026. Total assets are in the fund's base currency.
What does BIS.US invest in?
- Mostly Cash (191.3%)
- Top 3 holdings: 22.6% of the fund
Asset allocation
- Cash 191.3%
- Other 100.0%
Top holdings
- Amgen Inc 8.23%
- Vertex Pharmaceuticals Inc 7.30%
- Gilead Sciences Inc 7.06%
- Biogen Inc 6.02%
- Illumina Inc 5.82%
ProShares UltraShort Nasdaq Biotechnology performance
Sharpe ratio -1.45- This year
- -43.98%
- 1 year
- -46.77%
- 3 years
- -39.51%
- 5 years
- -21.38%
Volatility 29.5% over 1 year and 31.0% over 3 years. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
BIS.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About ProShares UltraShort Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund i…
Full fund profileProShares UltraShort Nasdaq Biotechnology top holdings
47.9% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Amgen Inc AMGN.US | Healthcare | United States | 8.23% |
| Vertex Pharmaceuticals Inc VRTX.US | Healthcare | United States | 7.30% |
| Gilead Sciences Inc GILD.US | Healthcare | United States | 7.06% |
| Biogen Inc BIIB.US | Healthcare | United States | 6.02% |
| Illumina Inc ILMN.US | Healthcare | United States | 5.82% |
| Regeneron Pharmaceuticals Inc REGN.US | Healthcare | United States | 4.00% |
| Alexion Pharmaceuticals Inc ALXN.US | Healthcare | United States | 3.14% |
| Seagen Inc SGEN.US | Healthcare | United States | 2.19% |
| Incyte Corporation INCY.US | Healthcare | United States | 2.17% |
| Biomarin Pharmaceutical Inc BMRN.US | Healthcare | United States | 2.00% |
The 10 largest of 104 holdings.
ProShares UltraShort Nasdaq Biotechnology fund profile
- Fund name
- ProShares UltraShort Nasdaq Biotechnology
- Ticker
- BIS.US
- Exchange
- USA Stocks
- Issuer
- ProShares
- Fund website
- proshares.com/funds/bis.html
- Index tracked
- -
- Category
- Leveraged & Inverse Equity
- Domicile
- United States
- Inception date
- Apr 6, 2010
- Trading currency
- USD
- Expense ratio
- 0.96%
About ProShares UltraShort Nasdaq Biotechnology
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.